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Mason–Pfizer monkey virus (M-PMV) proteinase, released by the autocatalytic cleavage of Gag-Pro and Gag-Pro-Pol
polypeptide precursors, catalyzes the processing of viral precursors to yield the structural proteins and enzymes of the
virion. In retroviruses, usually only one proteolytically active form of proteinase exists. Here, we describe an unusual
feature of M-PMV, the existence of three active forms of a retroviral proteinase with molecular masses of 17, 13, and
12 kDa as determined by mass spectroscopy. These forms arise in vitro by self-processing of a 26-kDa proteinase
precursor. We have developed a process for isolation of each truncated product and demonstrate that all three forms
display proteolytic activity. Amino acid analyses, as well as the determination of N- and C-terminal sequences, revealed
that the N-termini of all three forms are identical, confirming that in vitro autoprocessing of the 17-kDa form occurs at
the C-terminus to yield the truncated forms. The 17-kDa form and the newly described 13-kDa form of proteinase were
identified in virions collected from the rhesus monkey CMMT cell line chronically infected with M-PMV, confirming that
multiple forms exist in vivo. © 1998 Academic Press
INTRODUCTION
Mason–Pfizer monkey virus (M-PMV) was originally
isolated from a spontaneous mammary carcinoma in a
rhesus monkey (Chopra and Mason, 1970). While this
exogenous virus has not been demonstrated to be on-
cogenic (Fine et al., 1975; Fine and Schochetman, 1978),
it has been associated with an acquired immunodefi-
ciency (AIDS-like) syndrome in macaques (Daniel et al.,
1984; Marx et al., 1984; Stromberg et al., 1984) that is
distinct from that caused by SIV (simian immunodefi-
ciency virus). The most prominent characteristic of M-
PMV, as the prototypical D-type retrovirus, is the preas-
sembly of viral capsids within the cell cytoplasm (Som-
merfelt et al., 1992). These immature capsids are
subsequently transported to the plasma membrane,
where they extrude the plasma membrane and are re-
leased. The processes of assembly, intracellular trans-
port of immature capsids, and envelopment in D-type
retroviruses are separate and distinct steps, unlike those
in the C-type morphogenic pathway which assemble the
capsid shells during the process of budding from the
plasma membrane (Hunter, 1994).
The genomic organization of M-PMV consists of four
genes: 59 gag-pro-pol-env 39, where gag encodes the
polypeptide precursor Gag (Pr 78) composed of six struc-
tural proteins, pro encodes the viral proteinase, and pol
encodes the integrase and reverse transcriptase. During
the expression of the pro and pol genes, ribosomal
frameshifting occurs within the overlap of the gag-pro
and pro-pol reading frames, yielding two additional Gag-
containing polypeptide precursors, Pr 95 (Gag-Pro) and
Pr 180 (Gag-Pro-Pol). The N-terminal portion of the pro
region also encodes a dUTPase activity (Elder et al.,
1992). The M-PMV proteinase must cleave within each of
these precursors to yield structural proteins and viral
enzymes. This process, called maturation, coincides with
distinctive morphological changes. Inactivation of the PR
abolishes viral maturation and infectivity (Sommerfelt et
al., 1992). Despite the incorporation of the precursor
proteins into immature capsids in the cytoplasm, the
M-PMV proteinase (PR) remains inactive as a part of the
polyprotein precursors (Pr 95 and Pr 180) until a late
stage of virus release from the cell. Thus, activation of
proteinase must be a highly regulated process and M-
PMV therefore is an attractive experimental model for
studying how this might be mediated.
All retroviral PRs belong to the family of aspartic pro-
teinases. The active retroviral proteinase is a dimer com-
posed of two identical subunits, each of which contrib-
utes one-half of the active site. A key structural feature of
the PR homodimer is a four-stranded antiparallel b sheet
that results from an interaction of sequences at the
N-terminus of one subunit and the C-terminus of the
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second subunit (for review see Wlodawer and Erickson,
1993). In most retroviruses, there is a single mature
active form of proteinase, and mutations at either the N-
or the C-terminus inactivate the enzyme (Zybarath et al.,
1994; Burstein et al., 1992; Oertle and Spahr, 1990; Pi-
chova´ et al., 1992; Stewart and Vogt, 1994; Schatz et al.,
1997).
In our previous work we cloned a fragment that con-
tains a substantial part of the M-PMV pro reading frame
into construct pT7Q10 (Hrusˇkova´-Heidingsfeldova´ et al.,
1995). This expression vector codes for a 26-kDa precur-
sor that accumulates in insoluble inclusion bodies dur-
ing expression in Escherichia coli. M-PMV proteinase
precursor expressed in E. coli was previously shown to
undergo self processing in vitro to yield two proteolyti-
cally active proteins with molecular weights of about 17
and 12 kDa. Here, we show that autoprocessing of the
M-PMV proteinase precursor in vitro yields a total of
three proteolytically active enzymes that differ by molec-
ular mass and specific activities. The individual recom-
binant forms were isolated and characterized. We also
show that in virions two of these forms of proteinase, of
17 and 13 kDa molecular mass, have been detected. The
possible biological roles of these forms are discussed.
RESULTS AND DISCUSSION
The expression vector pGOT7Q (Hrusˇkova´-Heidings-
feldova´ et al., 1995) encodes a 26-kDa precursor that
accumulates in inclusion bodies during expression in E.
coli. Bacteria were harvested and lysed 70 min after
induction with IPTG. Inclusion bodies were separated
from soluble proteins by centrifugation and were dena-
tured in 9 M urea. Processing of the 26-kDa precursor
occurs during renaturation by dialysis from the urea
solution (Fig. 1, lane 1). The first product of autocatalytic
cleavage is a proteinase species of 17 kDa, but we
observed that it could be processed further into trun-
cated but still proteolytically active enzymes of 13 and 12
kDa, depending on pH and ionic strength. The purifica-
tion of the 17- and 13-kDa forms of the M-PMV PR
involves chromatography on QAE–Sephadex at pH 7.5
(Fig. 1, lane 2), which retains the high-molecular-weight
contaminants. An efficient separation of the 17- and 13-
kDa proteinase species was achieved on SE–Sephadex
(Fig. 1, lanes 3 and 4) due to different isoelectric points of
the individual forms, which were determined by isoelec-
tric focusing to be 9.1 and 6.4, respectively. The mixture
of PR 17 and PR 13, purified on QAE–Sephadex, was
stable in Tris–HCl buffer, pH 7.5, at 4°C for at least 1 year.
In contrast, under acidic conditions and in the presence
of 1 M NaCl an autocatalytic cleavage of these species
generates a shorter 12-kDa form within 5 days at 4°C
(Fig. 2A). To exclude the effect of nonspecific cleavage of
the PR 17, the M-PMV PR inhibitor PPYVPstATMT (Ki is
0.3 mM) (Hrusˇkova´-Heidingsfeldova´ et al., 1995) was
added to a sample of the isolated 17-kDa species in 0.05
M citrate buffer, pH 5.5, and 0.3 M NaCl at 4°C. Figure 2B
shows the processing of PR 17 in the presence of inhib-
itor. Without the inhibitor (Fig. 2A), the 13-kDa form arose
from the 17-kDa form in 3 days. On the fifth day, the
12-kDa form together with the 13- and 17-kDa forms was
detected in this sample. The inhibitor significantly
slowed down the processing of the 17-kDa form, such
that the 13-kDa form did not appear in the sample until
after 10 days (Fig. 2B) and the 12-kDa form was not
observed in the sample even after 30 days. The 17-kDa
form in the absence of the inhibitor was completely
processed into the 12-kDa form during this period
(Fig. 2A).
We have investigated the conditions that might prevent
autoprocessing of the individual forms and have found
that processing of PR 17 does not occur in buffer with pH
7.5 and without the NaCl at 220°C. The 13-kDa form is
stable at pH 6.5 and at the salt concentrations lower than
0.1 M at 4°C. The 12-kDa species can be stored at pH 5.0
in the presence of 1–2 M NaCl at 4°C indefinitely. Both
pH and ionic strength significantly influence the in vitro
processing of the proteinase precursor into its truncated
forms.
N-terminal sequencing of PR 17, PR 13, and PR 12 of
M-PMV PR has revealed that all forms have an identical
N-terminal sequence WVQPI-. These results support the
conclusion reported by Hrusˇkova´-Heidingsfeldova´ et al.,
(1995) that autocatalytic processing of the 26-kDa pro-
teinase precursor occurs first at the N-terminus in the
site SSDIY*WVQPI to yield the 17-kDa proteinase with a
FIG. 1. PAGE analysis of steps in the isolation of the 17-, 13-, and
12-kDa forms of M-PMV proteinase. Purification of proteinases on
QAE–Sephadex A25 was followed by separation of the individual forms
on SE–Sephadex C25 and analysis on SDS–PAGE. Dialysate of inclu-
sion bodies in Tris–HCl buffer, pH 7.0 (lane 1), QAE–Sephadex purified
material (lane 2), the 17-kDa form isolated from SE–Sephadex (lane 3),
the 13-kDa form, flow-through of SE–Sephadex (lane 4), and the 12-kDa
product of processing of the 13-kDa form at pH 5.5 and 1 M NaCl
(lane 5).
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C-terminal sequence (-FGNF) that maps with the C-ter-
minus of the pro reading frame. To define the molecular
masses of each of the proteinase species, we used ESI
mass spectrometry, and the results of these analyses are
summarized in Table 1. The molecular mass of PR 13 was
determined as 12,956 Da, which corresponds to a pro-
teinase that is seven amino acids longer than the 12-kDa
form described previously by Hruskova´-Heidingsfeldova´
et al. (1995). These data are in a good agreement with
amino acid analyses of PR 13 (data not shown) and are
consistent with proteinase with a C-terminal sequence
DIVTA.
In order to define the specific activities of the indi-
vidual forms of M-PMV PR, we determined their pro-
teolytic activities on a chromogenic peptide substrate
ATHQVY*NphVRKANH2 that is cleaved by the M-PMV
PR at the position marked by the asterisk. The 17-kDa
form displayed the highest specific activity. When its
activity is normalized to 100%, the specific activity of
PR 13 is 58% and that of PR 12 is 12%.
To determine whether any of the truncated proteinase
species that we have identified in vitro were present in
virus, we pelleted virions released from the CMMT cell
line that is chronically infected with M-PMV. The virus
pellet was resuspended in SDS loading buffer and virion-
associated viral proteins were separated on 15% resolv-
ing SDS–PAGE in parallel with the each of the forms
isolated from bacteria. For immunoblot analysis, proteins
were transferred to nitrocellulose membrane by electro-
blotting and reacted with polyclonal rabbit anti M-PMV
PR serum. Figure 3 shows that two proteinase species
are present in M-PMV virions and that these are of
identical size to the 17- and 13-kDa forms of proteinase
expressed in bacteria. The 12-kDa species that we de-
scribed previously and M-PMV PR breakdown products
were not detected in virions even after significant over-
loading of the gel.
To rule out the possibility that the 13-kDa form of the
proteinase was an artifact of the virion preparation pro-
FIG. 2. Kinetic analysis of PR 17 processing in the absence (A) or in the presence (B) of an M-PMV proteinase-specific inhibitor PPYVPstAMTM.
A 2 mM solution of the 17-kDa form of proteinase in 50 mM citrate buffer containing 0.3 M NaCl and 0.1% 2-mercaptoethanol was stored at 4°C in
the absence or in the presence of 2 mM inhibitor for the time shown. Aliquots were removed and analyzed on SDS–PAGE and silver-stained as
described under Materials and Methods.
TABLE 1
Molecular Masses of M-PMV Proteinase Forms Obtained
from Electrospray Ionization Mass Spectra






PR 12 12,246 6 2 12,243
PR 13 12,956 6 2 12,955
PR 17 16,965 6 2 16,963
a Average molecular masses calculated from available complete
amino acid sequences.
FIG. 3. Comparative Western blot of proteinase species in M-PMV
virions. M-PMV virions were prepared as described under Materials
and Methods and analyzed on SDS–PAGE/Western blot (lane 1), along-
side the three in vitro derived species. (Lane 2), 17/13 kDa forms; (lane
3) 17 kDa forms; (lane 4) 17/13/12 kDa forms; and (lane 5) 12 kDa form.
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cess, pulse–chase experiments were performed. For
these studies, we analyzed the kinetics of PR precur-
sor(s) processing in virions released from the Rhesus
monkey CMMT cell line. CMMT cells were pulse labeled
for 30 min with medium containing [35S]Met1[35S]Cys
and then chased with nonradioactive complete growth
medium for 1, 2, 4, and 16 h (see Materials and Methods).
An aliquot representing 5% of the released radiolabeled
virions was immunoprecipitated with a goat anti-M-PMV
antiserum, and the remaining 95% of the released virions
were immunoprecipitated with a rabbit anti-M-PMV PR
antiserum. This ratio was chosen with regard to the
5–10% efficiency of ribosomal frame-shifting that is nec-
essary for the synthesis of Gag-Pro polyprotein (Sonigo
et al., 1986). Released M-PMV virions can be observed
within 1 h, as evidenced by the presence of the p27(CA)
protein and p14(NC) protein (which migrates with a mo-
lecular mass of approximately 17 kDa in these gels; Fig.
4, lane 1). At this time, a protein migrating at 17 kDa
recognized by anti-PR serum can also be observed (Fig.
4, lane 2). After 2 h, the rabbit anti-PR antiserum recog-
nizes two distinct proteins, a 17-kDa band and a band
migrating at 13 kDa. It appears that the ratio of p17
versus p13 in released virions is established by 4 h and
does not change thereafter. This demonstrates that pro-
cessing of the proteinase molecule occurs also in vivo.
However, only the larger of the two truncated forms of the
proteinase could be detected in virions. Conditions
present within virions may stabilize the PR 17 and PR 13
forms.
Proteolytic cleavage of retroviral precursor polypro-
teins appears to be an essential control mechanism of
the virion maturation. Precursor processing mediated by
the virus-encoded proteinase occurs during or shortly
after the budding of immature particles from infected
cells. M-PMV, as a typical D-type retrovirus, preas-
sembles viral capsids within the cytoplasm of an infected
cell. Therefore, the proteinase activation as well as pre-
cursor processing itself must be tightly regulated events.
In most retroviruses a single form of the viral proteinase
is found and because the N- and C-termini play a key
role in protein folding, any alteration in these regions
influences proteinase activity. While a truncation of MAV
and RSV proteinases at the N-terminus by 1 and 3 amino
acids, respectively, results in inactivation (Pichova´ et al.,
1992; Schatz et al., 1997), the fusion of HIV-1 and ASLV
PRs with adjacent proteins at the N-terminus improves
the proteolytic activities of these molecules (Kotler et al.,
1992; Zybarath and Carter, 1995; Arad et al., 1995; Almog
et al., 1996). Truncation of FIV PR at the N-terminus by
five residues enhances the stability and the activity of
this enzyme, while autolysis at the C-terminus results in
inactivation (Laco et al., 1997). In contrast, M-PMV PR
can be processed at its C-terminus to yield two addi-
tional forms which retain relatively high levels of proteo-
lytic activity. The only other retroviral proteinase that has
been reported to retain activity following truncation is the
BLV proteinase (Precigoux et al., 1993; Hrusˇkova´-Heid-
ingsfeldova´, unpublished results).
The results described here allow us to hypothesize
that the individual forms of M-PMV proteinase may be
responsible for cleavage at different locations in the
virion or at different stages of maturation. The interplay of
the two proteinase species found in vivo may help to
regulate the cleavage cascade of Gag, Gag-Pro, and
Gag-Pro-Pol polyproteins in an ordered process in which
available cleavage sites are cleaved step by step at
different rates. Experiments are in progress to compare
the substrate specificity of M-PMV PR 17, PR 13, and PR
12 in vitro. In addition, by engineering M-PMV proviruses
that encode the individual forms of PR, it will be possible
to determine the role of these proteinase species in the
life cycle of the virus.
In addition to the essential role of retroviral protein-
ases in viral replication, the cytotoxic effect of these
proteinases in prokaryotic and eukaryotic cells has been
demonstrated (Shoeman et al., 1990; Tomasselli et al.,
1991; Kaplan and Swanstrom, 1991; Konvalinka et al.,
1995). Retroviral proteinases cleave a number of cellular
proteins of which the cleavage of the cytoskeletal pro-
teins vimentin, desmin, and actin by PRs (for review see
Sna´sˇel and Pichova´, 1996) may be responsible for this
cytotoxicity. Preliminary studies of the cleavage of vimen-
tin by different retroviral proteinases have revealed that
cleavage of vimentin is dependent upon the substrate
specificity of each enzyme, and it is possible that the
FIG. 4. M-PMV PR processing in vivo. Autoradiograph of metaboli-
cally labeled and immunoprecipitated proteins from M-PMV virions
released from CMMT cells 1 to 16 h after pulse-labeling with
[35S]Met1[35S]Cys protein labeling mix. 35S-labeled virus-associated
proteins were incubated with either goat polyclonal antiserum raised
against M-PMV virus particles (V) or rabbit polyclonal antiserum raised
against the bacterially expressed recombinant M-PMV PR (PR) and
separated on 15% resolving SDS–PAGE. Note that 19 times more
released radiolabeled virions were immunoprecipitated with the rabbit
anti M-PMV PR antiserum than with the goat anti M-PMV antiserum
(see Results).
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different forms of proteinase described here have differ-
ent specificities for cytoskeletal proteins.
MATERIALS AND METHODS
Cloning and bacterial expression
The construction of pGOT7Q for bacterial expression
of M-PMV proteinase was described previously (Hrusˇ-
kova´-Heidingsfeldova´ et al., 1995). The vector contains
the coding region for the M-PMV proteinase and flanking
sequences under the transcriptional control of the pro-
moter of bacteriophage T7 gene 10. Upon induction with
IPTG the 26-kDa proteinase precursor accumulates in
insoluble inclusion bodies.
Purification of M-PMV proteinases
E. coli cells harboring the M-PMV PR precursor were
suspended in 50 mM Tris–HCl, pH 8, containing 1 mM
EDTA, 50 mM NaCl, and 70 mM PMSF and were then
disrupted by X-press and freezing. The cells were treated
at room temperature with lysozyme for 20 min and then
with 1% aqueous sodium deoxycholate for 20 min. The
inclusion bodies were separated from the soluble cyto-
plasmic fraction by centrifugation. Inclusion bodies were
resuspended in 50 mM Tris–HCl, pH 7.5, containing 0.1%
2-mercaptoethanol, 30 mM NaCl, and 2 mM EDTA (Buffer
A) and were injected into a solution of 9 M urea in the
same buffer. Dialysis of the urea solution was carried out
against Buffer A. The supernatant obtained by centrifu-
gation of the dialyzed material was applied to a QAE–
Sephadex A 25 column equilibrated with Buffer A. While
impurities were bound to the column, pure proteinases
flowed through. To separate the 17- and 13-kDa forms of
the M-PMV proteinase, the pH of the fractions from the
QAE–Sephadex column was adjusted to 5.5 and these
fractions were loaded onto a SE–Sephadex C25 column
equilibrated with 20 mM sodium citrate buffer, pH 5.5,
containing 1 mM EDTA, 0.1% 2-mercaptoethanol, 0.01%
sodium azide, and 10% glycerol. The 13-kDa form flowed
through the column and the 17-kDa form was eluted from
the SE–Sephadex column with 50 mM Tris–HCl buffer,
pH 7.5, containing 0.1% 2-mercaptoethanol, 2 mM EDTA,
10% glycerol, and 0.5 M NaCl.
To isolate the 12-kDa form, the urea solution of inclu-
sion bodies was dialyzed initially against Buffer A. Two
hours later, dry Sephadex C25 was added into the dial-
ysis tubing and Buffer A was replaced with 50 mM
sodium acetate buffer, pH 5.2, containing 1 mM EDTA
and 0.1% 2-mercaptoethanol (Buffer B). After dialysis, the
Sephadex C-25 was separated using a glass filter and
washed with Buffer B. The active fractions were eluted
from SE Sephadex with buffer B containing 1 M NaCl.
Amino acid and N-terminal sequence analyses
Amino acid analysis was performed in a Durrum D500
analyzer. The samples were hydrolyzed for 20 h with 6 M
HCl containing 0.1% phenol and then dried by vacuum
desiccation. The N-terminal sequences were determined
using an Applied Biosystems 470A sequencer. The phe-
nylthiohydantoins were identified by HPLC on an Ultra-
sphere ODS column.
Proteolytic activity assay
Routinely, the activities of all forms of M-PMV PR were
assayed by cleavage of a peptide substrate ATHQVYN-
pHVRKA followed by evaluation of cleavage products by
RP-HPLC on a Vydac C18 RP column in a methanol/H2O
system (Hrusˇkova´-Heidingsfeldova´ et al., 1995). The
cleavage was performed at 37°C, pH 5.3, in buffer con-
taining 50 mM sodium acetate, 2 mM EDTA, 0.1% 2-mer-
captoethanol, 0.3 M NaCl. Typically, 20 ml of proteinase
of known concentration was added to 100 ml of 0.5 mmol
liter21 substrate. The reaction was stopped after 2 h by
the addition of 20% trifluoroacetic acid to a final concen-
tration of 2% (v/v). In order to compare specific activities
of the individual proteinase forms, the reaction condi-
tions were adjusted so that the conversion of the sub-
strate was lower than 20%. The concentration of protein-
ases was determined by the method of Bradford (1976).
The specific activity of proteinase is expressed as nano-
moles of converted substrate with 1 mg of proteinase at
37°C in 2 h.
Electrospray Ionization (ESI) mass spectrometry
All positive-ion ESI mass spectra were recorded on a
double-focusing Finnigan MAT 95 instrument (Finnigan
MAT, Bremen, FRG) with BE geometry (magnetic sector
preceding the electrostatic one) equipped with the Finni-
gan ESI source. Samples dissolved in 0.1% trifluoroacetic
acid (Merck) aqueous solution were continuously in-
fused through a stainless capillary held at 3.0 kV into the
electrospray ion source via a linear syringe pump at a
rate of 30 ml/min. A mixture of polypropylene glycols at
Mr of 1000, 2000, and 3000 was used to calibrate the m/z
scale of the mass spectrometer.
Antiserum
A purified 12-kDa form of M-PMV PR was used to
immunize three rabbits (Lampire Biological Laboratories,
Pipersville, PA). Following an initial priming in complete
Freund’s adjuvant (12.5 mg each subcutaneously and
intradermally), the rabbits were boosted by 25 mg in
complete Freund’s adjuvant twice intradermally and sub-
cutaneously and then seven times by 25 mg in incom-
plete Freund’s adjuvant intramuscularly at two to four
sites on the hind leg. The antisera were screened by
Western blot analysis of bacterially expressed PR and
those with the highest specific response were used for
the studies described.
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Virion purification
The rhesus monkey CMMT cell line, which chronically
produces M-PMV, was grown in Dulbecco’s essential
medium (RPMI) with 10% fetal bovine serum. Medium
containing released virions was collected from the con-
fluent plates and precleared by filtration through a mem-
brane filter (0.45 mm). Virions were then pelleted through
a 20% sucrose cushion in a virion suspension buffer (50
mM Tris–HCl, pH 7.5, 0.5 M NaCl, 10 mM EDTA, buffer C)
for 2 h at 107,000 g for 1 h (Beckman XL-80 Ultracentri-
fuge, Ti rotor SW 40). The virus pellet was resuspended
in the desired volume of SDS–PAGE loading buffer and
the proteins were separated on 10–20% SDS–PAGE. Viral
proteins were detected by immunoblot using polyclonal
rabbit anti-M-PMV PR antiserum, as described previ-
ously (Rhee and Hunter, 1990).
Metabolic labeling and immunoprecipitation
CMMT cells, chronically infected with M-PMV, were
washed twice in Dulbecco’s modified Eagle’s medium
without glutamine, methionine, and cysteine (ICN Bio-
medicals, Inc.) and then incubated in the same medium
at 37°C for 15 min prior to labeling. The cells were then
pulse-labeled for 30 min with 400 ml of the glutamine-,
cysteine-, and methionine-free media, containing 100
mCi of [35S]Cys1[35S]Met (DuPont, NEN Research Prod-
ucts) and chased for the indicated period in complete
growth medium. The culture medium containing radiola-
beled virus particles, which were released from the la-
beled cells, was collected and filtered through 0.45 mm
polysulfone membrane (Whatman). Virions were then
pelleted by centrifugation through a 20% sucrose cush-
ion in buffer C in a Beckman SW41 Ti rotor (12.5-ml tubes)
at 107,000 g for 1 h (Beckman XL-80 Ultracentrifuge). The
virus pellet was lysed in lysis buffer (0.1% SDS, 1% Triton
X-100, 1% sodium deoxycholate, 0.15 M NaCl, 0.05 M Tris,
pH 7.5) and virion-associated viral proteins were immu-
noprecipitated as described previously (Bradac and
Hunter, 1984) with goat anti-M-PMV antiserum (Division
of Cancer Cause and Prevention, National Cancer Insti-
tute) and with rabbit anti-M-PMV PR antiserum (see
above). Radiolabeled virus polypeptides were separated
on a 10–20% gradient or 15% resolving SDS–PAGE and
detected by autoradiography (Sambrook et al., 1989).
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